Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEODISCO
2024-516898-72-00Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine, cisplatin and pembrolizumab in hilar cholangiocarcinoma (HC) and cholangiocarcinoma (CCA) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Event-free survival. Planned start Nov 2025; status: authorised.
02
Drugs
03
Conditions
hilar cholangiocarcinoma (HC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2024-516898-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516898-72-00.